WC
KZR

Wexford Capital’s Kezar Life Sciences KZR Stock Holding History

Wexford Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,332
Closed -$22.1K – 257
2023
Q4 		$22.1K Buy
+2,332
New +$20.5K ﹤0.01% 187

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wexford Capital's KZR Position: Q1 2024 in Review

Wexford Capital sold out of Kezar Life Sciences (KZR) in Q1 2024, closing a stake of 2,332 shares — an estimated $22.1K sold.

Wexford Capital first reported a position in KZR in Q4 2023 and held it in 1 quarter. The position peaked at $22.1K in Q4 2023. 85 funds tracked by Wall St. Rank hold KZR as of Q1 2024.

  • Wexford Capital reported no remaining Kezar Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Wexford Capital sold 2,332 Kezar Life Sciences shares in Q1 2024, an estimated $22.1K.
  • Wexford Capital first reported a position in Kezar Life Sciences in Q4 2023 and held it in 1 quarter.
  • Wexford Capital's Kezar Life Sciences position peaked at $22.1K in Q4 2023.
  • 85 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.